EP3802598
DLL3/CD3 bindandi prótín fyrir krabbameinsmeðhöndlun
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
7.6.2019EP published:
12.2.2025EP application number:
19728454.0
EP translation filed:
3.4.2025Grant published:
15.5.2025EPO information:
European Patent Register
Max expiry date:
6.6.2039Expiry date:
6.6.2026Next due date:
30.6.2026
Title in English:
DLL3/CD3 BINDING PROTEINS FOR CANCER TREATMENTLanguage of the patent:
English
Timeline
Today
7.6.2019EP application
12.2.2025EP Publication
3.4.2025Translation submitted
15.5.2025Registration published
6.6.2026Expires
Owner
Name:
Boehringer Ingelheim International GmbHAddress:
Binger Strasse 173, 55216 Ingelheim am Rhein, DE
Inventor
Name:
HIPP, SusanneAddress:
55216 Ingelheim am Rhein, DE
Name:
ADAM, PaulAddress:
55216 Ingelheim am Rhein, DE
Name:
DZIEGELEWSKI, MichaelAddress:
Ridgefield, Connecticut 06877-0368, US
Name:
GANESAN, RajkumarAddress:
Ridgefield, Connecticut 06877-0368, US
Name:
GORMAN, Philip NicholasAddress:
Ridgefield, Connecticut 06877-0368, US
Name:
GUPTA, PriyankaAddress:
Ridgefield, Connecticut 06877-0368, US
Name:
GUPTA, PankajAddress:
Ridgefield, Connecticut 06877-0368, US
Name:
SCHEER, JustinAddress:
Ridgefield, Connecticut 06877-0368, US
Name:
VOYNOV, Vladimir H.Address:
Ridgefield, Connecticut 06877-0368, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
18176888Date:
9.6.2018Country:
EP
Number:
18176889Date:
9.6.2018Country:
EP
Number:
19159321Date:
26.2.2019Country:
EP
Classification
Categories:
C07K 16/28, A61K 39/00
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 10.6.2025
Expires: 6.6.2026
Payer: G.H. Sigurgeirsson ehf.